The U.S. Food and Drug Administration (FDA) has expanded approval for Linzess (linaclotide), allowing the prescription medication to be used in children as young as 2 years old who suffer from functional constipation. The announcement marks an important advancement for pediatric gastrointestinal care, especially for families struggling to manage chronic constipation in younger children.
Previously, Linzess was approved only for pediatric patients aged 6 years and older with functional constipation. With this latest FDA decision, children between the ages of 2 and 5 can now access the medication under medical supervision. Linzess remains the first and only FDA-approved prescription treatment specifically indicated for pediatric functional constipation.
Functional constipation is a common digestive condition that affects many children worldwide. It is characterized by infrequent bowel movements, hard stools, painful bowel movements, and difficulty passing stool. Unlike constipation caused by an underlying medical disease, functional constipation occurs without a structural or biochemical cause.
The condition is particularly common in preschool-aged children. Symptoms can disrupt daily routines, cause abdominal discomfort, and negatively affect quality of life for both children and parents. In many cases, over-the-counter remedies and lifestyle adjustments do not provide sufficient relief.
Healthcare professionals say managing constipation in very young children can be especially difficult because treatment options are limited and younger patients may struggle with medication adherence.
The FDA’s expanded approval was supported by data from a 12-week Phase 3 clinical trial involving children aged 2 to 5 years with functional constipation. The randomized, placebo-controlled study evaluated the safety and effectiveness of Linzess at a 72 mcg dose.
According to trial findings, children treated with Linzess experienced improved spontaneous bowel movement frequency compared with those receiving a placebo. Researchers also reported that the medication’s safety profile was generally consistent with previous studies conducted in adults and older pediatric patients.
Medical experts believe the approval provides physicians with an additional evidence-based option for managing chronic constipation in younger children.
Linzess contains the active ingredient linaclotide, which belongs to a class of medications known as guanylate cyclase-C agonists, or GC-C agonists. The medicine works by increasing fluid secretion in the intestines, helping stool move more easily through the digestive tract.
The medication may also help reduce the activity of pain-sensing nerves in the intestines, although the clinical significance of this effect is still being studied.
Linzess is taken once daily and comes in capsule form. For younger children who may have difficulty swallowing capsules, parents can mix the capsule contents with applesauce or water, making administration easier.
The expanded indication addresses what many healthcare providers describe as a significant gap in pediatric gastrointestinal treatment. Before this approval, there were limited prescription therapies specifically designed for younger children with functional constipation.
Ironwood Pharmaceuticals, the company behind Linzess, stated that the FDA granted the application priority review due to the unmet medical need in this patient population.
Since its original launch in 2012, Linzess has been prescribed to more than 5.5 million patients in the United States. The drug is widely used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.
The newly expanded pediatric indication may further strengthen Linzess’ role in gastrointestinal care, particularly among pediatric gastroenterologists seeking reliable long-term treatment options.
Although Linzess can help relieve constipation symptoms, parents and caregivers should be aware of important safety considerations.
The medication carries a boxed warning regarding the risk of serious dehydration in children younger than 2 years old. Animal studies involving neonatal mice showed severe dehydration and death after exposure to linaclotide.
Because of this risk, Linzess is strictly contraindicated in patients under the age of 2.
The most commonly reported side effect associated with Linzess is diarrhea. In some cases, diarrhea may become severe and require treatment interruption and rehydration.
Other possible side effects include:
Parents should contact a healthcare provider if severe diarrhea or dehydration symptoms develop while a child is taking the medication.
Pediatric constipation is often underestimated, yet it can become a chronic issue that affects a child’s emotional and physical wellbeing. Children with persistent constipation may avoid school activities, develop anxiety related to bowel movements, or experience ongoing abdominal pain.
Experts say having an FDA-approved prescription option specifically studied in younger children could improve treatment outcomes and help clinicians create more personalized care plans.
The approval may also encourage additional research into pediatric gastrointestinal disorders and increase awareness about digestive health in children.
As awareness of pediatric digestive disorders grows, pharmaceutical companies and healthcare providers continue searching for more effective and child-friendly therapies. The expanded use of Linzess may represent a broader trend toward developing specialized GI treatments for younger patients.
Doctors still recommend that treatment for functional constipation include lifestyle and dietary modifications whenever appropriate. Increased fiber intake, hydration, regular physical activity, and healthy toilet habits remain important parts of constipation management.
However, for children who do not respond adequately to conservative therapies, prescription medications like Linzess may provide additional relief and support long-term symptom control.
The FDA approval of Linzess for children aged 2 to 5 with functional constipation marks a major milestone in pediatric gastrointestinal medicine. By expanding access to a prescription treatment option for younger children, healthcare providers now have another tool to help manage a condition that can significantly impact daily life.
Parents considering Linzess for their child should speak with a qualified healthcare professional to determine whether the medication is appropriate based on individual medical history and symptoms.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting or changing any medication or treatment plan for a child or adult.
Ironwood Pharmaceuticals, Inc.
Di Lorenzo C, Hyams JS, Saps M, et al. Chapter 16: Childhood Functional Gastrointestinal Disorders: Child/Adolescent. In: Drossman DA, Chang L, Chey WD, et al. Rome IV: Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction. Raleigh, NC: Rome Foundation; 2016.
Paul A, Setya A, Lawrence VN. Pediatric Functional Constipation. StatPearls. Available: https://www.ncbi.nlm.nih.gov/books/NBK537037/.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.